Open AccessThe utility of evaluating mismatch repair proteins in endometrial carcinoma: an experience from a tertiary referral centre in North India
Author(s) -
Ekta Jain,
Sudhakar Prasad,
Aparna Dhar,
Lata Kini,
Shivani Sharma,
Aditi Dewan
Publication year - 2021
Publication title -
pathologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.243
H-Index - 18
eISSN - 1591-951X
pISSN - 0031-2983
DOI - 10.32074/1591-951x-129
Subject(s) - lynch syndrome , msh6 , msh2 , endometrial cancer , microsatellite instability , pms2 , medicine , mlh1 , oncology , family history , uterine cancer , malignancy , cancer , carcinoma , dna mismatch repair , gynecology , pathology , biology , colorectal cancer , allele , biochemistry , microsatellite , gene
Endometrial cancer (EC) is a common gynecological malignancy. Around 25-30% patients have mismatch repair deficiency (MMRd). Lynch syndrome is caused by germline mutations in MMR genes. Lynch-associated tumours have better prognosis, however implications for prognosis and survival is less known. Microsatellite insufficiency (MSI) is associated with high neoantigen loads and number of tumor infiltrating lymphocytes, which overexpresses PD-1 and PD-L1 and are excellent candidates for PD-1-targeted immunotherapies. In this study, we aim to evaluate the utility of MMR in patients with EC and its clinico-pathological correlation.